Both in Biotechnology
SAB Biotherapeutics vs Kyverna Therapeutics
Over the past year SABS returned +3.1% and KYTX returned −18.7%; their daily moves had a correlation of 0.30.
SABS +3.1% KYTX −18.7%Growth of $1, one year, split-adjusted
| Metric | SABS | KYTX |
|---|---|---|
| Price | $3.35 | $5.67 |
| Market cap | $304.8M | $350.7M |
| Today | +3.72% | −3.08% |
| 1 month | +9.5% | −13.0% |
| 6 months | −3.5% | −36.1% |
| Year to date | −10.4% | −39.7% |
| 1 year | +10.2% | −20.9% |
| Revenue growth (YoY) | — | — |
| Gross margin | — | — |
| Net margin | — | — |
| P/E (TTM) | — | — |
| Price / sales | — | — |
| Net cash | $99.4M | $174.4M |
| Dividend yield | — | — |
| Volatility (60d) | 55.7% | 58.2% |
| Short % of float | 6.2% | 26.6% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).